Marathon Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MetLife
MET
|
+$2.6M |
| 2 |
GSK
GSK
|
+$1.74M |
| 3 |
DOC
PHYSICIANS REALTY TRUST
DOC
|
+$1.53M |
| 4 |
Quanterix
QTRX
|
+$964K |
| 5 |
TPC
Tutor Perini Cor
TPC
|
+$914K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
T. Rowe Price
TROW
|
+$15.1M |
| 2 |
Enphase Energy
ENPH
|
+$3.56M |
| 3 |
Apple
AAPL
|
+$3.36M |
| 4 |
TechTarget
TTGT
|
+$964K |
| 5 |
Targa Resources
TRGP
|
+$863K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 52.74% |
| 2 | Technology | 13.71% |
| 3 | Healthcare | 10.36% |
| 4 | Industrials | 7.51% |
| 5 | Energy | 4.3% |
Similar funds
Marathon Capital Management's Q2 2020 Portfolio in Review
As of Q2 2020, Marathon Capital Management held 149 positions worth $260M, up 20% from $218M the previous quarter. Its ten largest holdings account for 61% of the portfolio.
Marathon Capital Management withdrew a net $10.2M in Q2 2020, closing 9 positions and reducing 60 holdings. Its most notable exit was TechTarget, an estimated $964K position sold in full.
By sector, the portfolio is most concentrated in Financials at 53% of assets, down from 55% a quarter earlier, followed by Technology and Healthcare.
Against the trend, Marathon Capital Management opened a new position in PHYSICIANS REALTY TRUST worth $1.64M.
- Marathon Capital Management's largest Q2 2020 buy was PHYSICIANS REALTY TRUST: 93,525 shares worth $1.64M.
- Marathon Capital Management added most to MetLife in Q2 2020, an estimated $2.6M increase.
- Marathon Capital Management's biggest Q2 2020 reduction was T. Rowe Price, cutting an estimated $15.1M.
- Marathon Capital Management fully exited TechTarget in Q2 2020, selling an estimated $964K.
- Marathon Capital Management's ten largest holdings make up 61% of its $260M portfolio in Q2 2020.
- Marathon Capital Management opened 27 new positions and closed 9 in Q2 2020.
- Marathon Capital Management's portfolio value rose 20% quarter-over-quarter to $260M.
Based on Marathon Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.